Myosana Therapeutics

Get a Piece of Myosana Therapeutics

https://wefunder.com/myosana.therapeutics

Total raised on Wefunder: 538646

Total investors: 27

Quick facts

  • Developing a gene therapy treatment for Duchenne muscular dystrophy (DMD).
  • Designed to deliver full-length dystrophin to skeletal and cardiac muscle.
  • Uses proprietary GLUT4-targeting antibodies to deliver DNA to muscle cells efficiently.
  • Non-viral design allows repeat dosing, unlike most viral gene therapies.
  • Investment from Parent Project Muscular Dystrophy, CureDuchenne Ventures, angel investor.
  • Preclinical studies show significant dystrophin expression in DMD animal models.
  • DMD treatment market projected to reach about $10B by 2030.
  • A founding team with extensive experience in neuromuscular disease research and drug development.

Team profiles

Featured investor profiles

Invest in Myosana Therapeutics

Get a Piece of Myosana Therapeutics

FIRST GOAL HIT (You can still invest)

$538,646

raised from 27 investors
INVESTMENT TERMS
Future Equity
$27.384M valuation cap

What Investors Say

LEAD INVESTOR
Invested $50,000 this round + $4,050,000 previously
I have seen across the course of my career the massive difference formulation and delivery platforms can make to the efficacy of nucleic acid-based (and other) therapies and prophylactics. I strongly believe the GLUT4 entry target will allow for the precise delivery of full-length genes to address DMD and other diseases. Furthermore, the safety of non viral and non immunogenic delivery modes in situations where chronic treatment is needed, make the platform binder adaptability a potentially utilitarian approach across multiple cell types.
What People Say